Evidence for moxifloxacin in community-acquired pneumonia: The impact of pharmaco-economic considerations on guidelines

Current Medical Research and Opinion

Volumn 25, Issue 10, 2009, Pages 2447-2457

  Simoens, Steven ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Community acquired pneumonia; Cost effectiveness; Guidelines; Moxifloxacin; Pharmaco economics; Resistance

Indexed keywords

AMINOGLYCOSIDE; AMINOPENICILLIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFUROXIME; CEPHALOSPORIN; CIPROFLOXACIN; CLARITHROMYCIN; DOXYCYCLINE; GEMIFLOXACIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ROXITHROMYCIN; TELITHROMYCIN; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE INFECTION; COCHRANE LIBRARY; COMMUNITY ACQUIRED PNEUMONIA; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG MEGADOSE; DRUG RESISTANCE; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; HAEMOPHILUS INFLUENZAE; HEALTH CARE COST; HUMAN; MEDLINE; MORAXELLA CATARRHALIS; NOTE; PHARMACOECONOMICS; RISK FACTOR; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COMMUNITY-ACQUIRED INFECTIONS; COST-BENEFIT ANALYSIS; DIARRHEA; DRUG RESISTANCE, MICROBIAL; ECONOMICS, PHARMACEUTICAL; HUMANS; PNEUMONIA, BACTERIAL; PRACTICE GUIDELINES AS TOPIC; QUINOLINES;

EID: 70349308548     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903223663     Document Type: Note

References (56)

1. Almirall J, Bolibar I, Vidal J, et al. Epidemiology of community-acquired pneumonia in adults: a population-based study. Eur Respir J 2000;15:757-763 (Pubitemid 30196306)
2. Jokinen C, Heiskanen L, Juvonen H, et al. Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland. Am J Epidemiol 1993;137:977-988 (Pubitemid 23191065)
3. Anderson RN. Deaths: leading causes for 2000. Natl Vital Stat Rep 2002;50:1-86
4. Talwar A, Lee H, Fein A. Community-acquired pneumonia: what is relevant and what is not? Curr Opin Pulm Med 2007;13:177-185
5. Grossman RF, Rotschafer JC, Tan JS. Antimicrobial treatment of lower respiratory tract infections in the hospital setting. Am J Med 2005;118(Suppl. 7A):29-38
6. Niederman MS, McCombs JS, Unger AN, et al. The cost of treating community- acquired pneumonia. Clin Ther 1998;20:820-837 (Pubitemid 28421502)
7. Lave JR, Lin CJ, Fine MJ, et al. The cost of treating patients with community-acquired pneumonia. Semin Respir Crit Care Med 1999;20:189-197 (Pubitemid 29277759)
8. Aliyu ZY, Aliyu MH, McCormick K. Determinants for hospitalization in 'low-risk' community acquired pneumonia. BMC Infect Dis 2003;3:11
9. Talwar A, Lee H, Fein A. Community-acquired pneumonia: what is relevant and what is not? Curr Opin Pulm Med 2007;13:177-185
10. Kuti JL, Capitano B, Nicolau DP. Cost-effective approaches to the treatment of community-acquired pneumonia in the era of resistance. Pharmacoeconomics 2002;20:513-528 (Pubitemid 34848337)
11. Blondeau J. A review of the comparative in vitro activities of 12 antimicrobial agents, with a focus on five new respiratory quinolones. J Antimicrob Chemother 1999;43:1-11 (Pubitemid 29231787)
12. Miravittles M. Moxifloxacin in respiratory tract infections. Expert Opin Pharmacother 2005;6:283-293
13. Summary of Product Characteristics: Avelox, INN moxifloxacin 400 mg. London: European Medicines Agency, 2002. Available at: www.emea.europa.eu/pdfs/ human/referral/avelox/Avelox-Annex%20I-III-en.pdf [Last accessed 27 October 2008]
14. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005;26:1138-1180 (Pubitemid 41829947)
15. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44(Suppl. 2):S27-72 (Pubitemid 46290553)
16. Cortoos PJ, De Witte K, Peetermans W, et al. Opposing expectations and suboptimal use of a local antibiotic hospital guideline: a qualitative study. J Antimicrob Chemother 2008;62:189-195 (Pubitemid 351865896)
17. National Institute for Health and Clinical Excellence. Available at: http://www.nice.org.uk [Last accessed 3 July 2009]
18. Drummond M, Sculpher MJ, Torrance GW, et al. Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press, 2005
19. Welte T. Making the right choices for your CAP patient. Presentation at the Annual Congress of the European Respiratory Society. Berlin, 4-8 October 2008
20. Martin M, Quilici S, File T, et al. Cost-effectiveness of empirical prescribing of antimicrobials in community-acquired pneumonia in three countries in the presence of resistance. J Antimicrob Chemother 2007;59:977-989 (Pubitemid 47073371)
21. Martin M, Moore L, Quilici S, et al. A cost-effectiveness analysis of antimicrobial treatment of community-acquired pneumonia taking into account resistance in Belgium. Curr Med Res Opin 2008;24:737-751
22. Moore L, Martin M, Quilici S, et al. The cost-effectiveness of targeted prescribing of antimicrobials in Canada for community-acquired pneumonia in an era of antimicrobial resistance. Value Health 2008;11:A271-72
23. Sabes-Figuera R, Segu JL, Puig-Junoy J, et al. Influence of bacterial resistances on the efficiency of antibiotic treatments for community-acquired pneumonia. Eur J Health Econ 2008;9:23-32
24. Torres A, Muir JF, Corris P, et al. Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia. Eur Respir J 2003;21:135-143 (Pubitemid 36150313)
25. Petitpretz P, Arvis P, Marel M, et al. Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults. Chest 2001;119:185-195 (Pubitemid 32150566)
26. Hoeffken G, Meyer HP, Winter J, et al. The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia. Respir Med 2001;95:553-564 (Pubitemid 32624519)
27. Faich GA, Morganroth J, Whitehouse AB, et al. Clinical experience with moxifloxacin in patients with respiratory tract infections. Ann Pharmacother 2004;38:749-754 (Pubitemid 38509046)
28. Leophonte P, File T, Feldman C. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin. Respir Med 2004;98:708-720 (Pubitemid 38842773)
29. Higuera F, Hidalgo H, Feris J, et al. Comparison of oral cefuroxime axetil and oral amoxycillin/clavulanate in the treatment of community-acquired pneumonia. J Antimicrob Chemother 1996;37:555-564 (Pubitemid 26116970)
30. Mathers DL, Hassman J, Tellier G. Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults. Clin Ther 2004;26:48-62 (Pubitemid 38241522)
31. Tellier G, Niederman MS, Nusrat R, et al. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. J Antimicrob Chemother 2004;54:515-523 (Pubitemid 39177479)
32. Gordon KA, Biedenbach DJ, Jones RN. Comparison of Streptococcus pneumoniae and Haemophilus influenzae susceptibilities from community-acquired respiratory tract infections and hospitalized patients with pneumonia: five-year results for the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 2003;46:285-289
33. Cabre M. Pneumonia in the elderly. Curr Opin Pulm Med 2009;15:223-229
34. Mills GD, Oehley MR, Arrol B. Effectiveness of beta lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta-analysis. BMJ 2005;330:456 (Pubitemid 40320547)
35. Drummond MF, Becker DL, Hux M, et al. An economic evaluation of sequential IV/po moxifloxacin therapy compared to IV/po co-amoxiclav with or without clarithromycin in the treatment of community-acquired pneumonia. Chest 2003;124:526-535 (Pubitemid 37000129)
36. Bauer TT, Welte T, Ernen C, et al. Cost analyses of community-acquired pneumonia from the hospital perspective. Chest 2005;128:2238-2246 (Pubitemid 41507565)
37. Lloyd A, Battleman D, Choudhri S, et al. Cost-effectiveness analysis of intravenous moxifloxacin compared to levofloxacin in hospitalized elderly patients with community-acquired pneumonia. Presentation at the 6th European Congress of Clinical Microbiology and Infectious Diseases. Nice, 1-4 April 2006
38. Davis SL, Delgado G, McKinnon PS. Pharmacoeconomic considerations associated with the use of intravenous-to-oral moxifloxacin for community-acquired pneumonia. Clin Infect Dis 2005;41(Suppl. 2):136-143
39. Robenshtok E, Shefet D, Gafter-Gvili A, et al. Empiric antibiotic coverage of atypical pathogens for community acquired pneumonia in hospitalized adults. Cochrane Database of Systematic Reviews, 2008, Issue 1. Art. No.: CD004418. DOI: 10.1002/14651858.CD004418.pub3
40. Baxter R, Ray GT, Fireman BH. Case-control study of antibiotic use and subsequent Clostridium difficile-associated diarrhea in hospitalized patients. Infect Control Hosp Epidemiol 2008;29:44-50 (Pubitemid 351267773)
41. Deshpande A, Pant C, Jain A, et al. Do fluoroquinolones predispose patients to Clostridium difficile associated disease? A review of the evidence. Curr Med Res Opin 2008;24:329-333 (Pubitemid 351294381)
42. Lynch 3rd JP, Zhanel GG. Streptococcus pneumoniae: does antimicrobial resistance matter? Semin Respir Crit Care Med 2009;30:210-238
43. Jones ME, Blosser-Middleton RS, Critchley IA, et al. In vitro susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a European multicenter study during 2000-2001. Clin Microbiol Infect 2003;9:590-599
44. Valcke Y. CAP guidelines: why differences between Belgian and American/ Canadian guidelines? Louvain: Université Catholique de Louvain, 2001. Available at: www.farm.ucl.ac.be/seminfec//Atelier-Mandell-23-11-01/Valcke/ Valcke.pdf [Last accessed 25 February 2008]
45. Jacobs MR, Felmingham D, Appelbaum PC, et al. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003;52:229-246
46. Green K, McGeer A, Plevneshi A, et al. on behalf of the Canadian Bacterial Surveillance Network. Trends in antimicrobial resistance in S. pneumoniae, Canada, 1993-2007. Presentation at the 18th European Congress of Clinical Microbiology and Infectious Diseases. Barcelona, 19 April 2008
47. Goldstein F, Bryskier A, Appelbaum PC, et al. The etiology of respiratory tract infections and the antibacterial activity of fluoroquinolones and other oral antibacterial agents against respiratory pathogens. Clin Microbiol Infect 1998;4(Suppl. 2):S8-S18 (Pubitemid 28209758)
48. Simoens S, Verhaegen J, Laekeman G, et al. Treating respiratory tract infections in ambulatory care in Belgium: fluoroquinolone consumption and resistance development. Int J Antimicrob Agents 2005;26:62-68 (Pubitemid 40854118)
49. Institut Pasteur. Evolution of fluoroquinolone resistance and detection of resistance mechanisms in clinical isolates of streptococcus pneumoniae collected in Belgium in 1995 - 2005. Brussels: Institut Pasteur, 2006. Available at:www.pasteur.be/pasteur-fr/index5930.html?page=antibiotic-research [Last accessed 21 October 2008]
50. Low DE. Managing antibiotic resistance: resistance patterns and effects on practice. Canadian Bacterial Surveillance Network. Available at: http://microbiology.mtsinai.on.ca/research/cbsn/cbsnnews/cbsn2005-eng.pdf [Last accessed 29 October 2008]
51. Doern GV, Richter SS, Miller A, et al. Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes? Clin Infect Dis 2005;41:139-148
52. Hoban D, Felmingham D. The PROTEKT surveillance study: antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis from community- acquired respiratory tract infections. J Antimicrob Chemother 2002;50(Suppl. S1):49-59 (Pubitemid 35049519)
53. Felmingham D, Reinert RR, Hirakata Y, et al. Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and compatative in vitro activity of the ketolide, telithromycin. J Antimicrob Chemother 2002;50(Suppl. S1):25-37 (Pubitemid 35049517)
54. Torrance G, Walker V, Grossman R, et al. Economic evaluation of ciprofloxacin compared with usual antibacterial care for the treatment of acute exacerbations of chronic bronchitis in patients followed for 1 year. Pharmacoeconomics 1999;16:499-520 (Pubitemid 29530153)
55. MacDougall C, Powell JP, Johnson CK, et al. Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals. Clin Infect Dis 2005;41(4):435-440 (Pubitemid 41099634)
56. Ray GT, Baxter R, DeLorenze GN. Hospital-level rates of fluoroquinolone use and the risk of hospital-acquired infection with ciprofloxacin-non susceptible Pseudomonas aeruginosa. Clin Infect Dis 2005;41(4):441-449 (Pubitemid 41099635)